Using genetic testing to guide care for non-autoimmune diabetes
Tests whole genome sequencing to guide diagnosis and treatment in adults with diabetes.
Plain-language title generated from the registry record
Registry title: Translating Genetic Knowledge Into Clinical Care in Non-Autoimmune Diabetes
Key facts
- Where
- Copenhagen, Herlev, Hillerød, and Hvidovre, DenmarkSee the 5 sites
Where in Denmark
- RigshospitaletCopenhagen, DenmarkNo longer taking part
- Herlev HospitalHerlev, DenmarkNo longer taking part
- Steno Diabetes Center CopenhagenHerlev, DenmarkNo longer taking part
- Hillerød HospitalHillerød, DenmarkNo longer taking part
- Hvidovre HospitalHvidovre, DenmarkNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Copenhagen
- Trial code
- NCT05368220
- Record updated
- 17 May 2022
- Original description
The aim of TRANSLATE is to implement genetic information directly into patient care to improve diagnosis and treatment of non-autoimmune diabetes. This project is the first large-scale implementation of systematic genetic testing within a common, non-communicable, chronic disease in Denmark, and will spearhead efforts to advance personalized medicine in Denmark.Read full original descriptionShow less
TRANSLATE - Translating Genetic Knowledge Into Clinical Care in Non-Autoimmune Diabetes
The aim of TRANSLATE is to implement genetic information directly into patient care to improve diagnosis and treatment of non-autoimmune diabetes. This project is the first large-scale implementation of systematic genetic testing within a common, non-communicable, chronic disease in Denmark, and will spearhead efforts to advance personalized medicine in Denmark.
The project will contribute to establishing technology, workflow, and evidence on how to implement and communicate actionable genetic information to clinicians and patients in a generalized format. These developments are pivotal for personalized medicine to reach broader clinical application.
Inclusion: Any case of non-T1D defined as debut >30 years of age, OR debut <30 years of age AND negative autoantibodies; Any case of diabetes diagnosed in pregnancy (obstetric departments).
Exclusion: Age <18 years; Inability to provide informed consent.